Since the human genome was first sequenced in 2000, genome science has accelerated at a remarkable rate. Rapid advances in DNA-sequencing technology mean that affordable decoding of the human genome is not far away. In fact, human genomes could be sequenced for as little as US$1,000 in the next few years. Unfortunately, the current biomedical research establishment is entirely unprepared for such a scenario.
Researchers often believe that their mission is to uncover new biology and genetics, and that someone else will translate them to the clinical arena. Accordingly, many geneticists have worked on “big-science” genomics, including genome-wide association studies focused on common genetic variations in the human species.
However, it is widely known that certain mutations can run in families, increasing dramatically the risks of certain diseases — for example, breast cancer, sickle-cell anemia and cystic fibrosis. Unfortunately, many human molecular geneticists have abdicated any responsibility for trying to decrease the overall burden of such diseases.
While this trend has many causes — most of which have been debated extensively — one very important factor is rarely discussed. Scientific research — and biomedical research in particular — largely resembles a race. Human geneticists, like big-game hunters, specialize in finding disease genes — the “prize.” Once they succeed, they usually do not continue to develop their findings; instead, they move on to their next target.
Today, scientists are rewarded for how many papers they publish and in which journals. In the US, several major genome-sequencing centers exist primarily to conduct research — including the Centers for Mendelian Genomics, which seek to find the genetic basis of “simple” Mendelian disorders (diseases caused by a single mutation in the structure of DNA). Many other countries are undertaking similar programs.
However, the discoveries and published papers rarely benefit the people who enable this research by donating their blood and other tissue samples. As Michael Nielsen discusses in his recent book Reinventing Discovery, the “publish or perish” mentality that dominates the field means that many substandard or incomplete papers are published, while those people who are supposed to benefit from the research are often little more than an afterthought.
Indeed, research volunteers rarely receive their genomic data, which betrays the trust that participants place in researchers to use their findings not only to increase the stock of scientific knowledge, but also to deliver actionable results.
The personal genomics and biotechnology company 23andMe has created a useful interface for returning results, which could easily be built upon to deliver complete genome data to participants — as long as the sample collection and sequencing are performed to a sufficiently high clinical standard.
The company’s model laudably calls for research participants to help in the analysis of their own genomes, thereby relieving researchers of the burden of returning all results at once.
With expanding knowledge, analyzing genomes becomes easier. The hope is that, as technology develops, more researchers will recognize the importance of returning results — especially those that could have a significant medical impact — to participants.
Because there is no regulation requiring that initial sequencing of human genomes be performed to clinical standards, most sequencing does not meet laboratory-test criteria. Indeed, results are often not reproducible — badly conceived, poorly conducted or outright fraudulent. Criteria must therefore be established to ensure that sequencing is performed in an appropriate clinical environment, with rigorous standards in place, including for sample collection.
Researchers today face the wrong incentives, which results in the failure to translate findings into meaningful action for research participants. Only by improving clinical standards and returning results to participants can human genome sequencing truly serve its purpose — to help humanity.
Gholson Lyon is an assistant professor in human genetics at Cold Spring Harbor Laboratory, New York, and a research scientist at the Utah Foundation for Biomedical Research.
Copyright: Project Syndicate
Congressman Mike Gallagher (R-WI) and Congressman Raja Krishnamoorthi (D-IL) led a bipartisan delegation to Taiwan in late February. During their various meetings with Taiwan’s leaders, this delegation never missed an opportunity to emphasize the strength of their cross-party consensus on issues relating to Taiwan and China. Gallagher and Krishnamoorthi are leaders of the House Select Committee on the Chinese Communist Party. Their instruction upon taking the reins of the committee was to preserve China issues as a last bastion of bipartisanship in an otherwise deeply divided Washington. They have largely upheld their pledge. But in doing so, they have performed the
It is well known that Chinese President Xi Jinping’s (習近平) ambition is to rejuvenate the Chinese nation by unification of Taiwan, either peacefully or by force. The peaceful option has virtually gone out of the window with the last presidential elections in Taiwan. Taiwanese, especially the youth, are resolved not to be part of China. With time, this resolve has grown politically stronger. It leaves China with reunification by force as the default option. Everyone tells me how and when mighty China would invade and overpower tiny Taiwan. However, I have rarely been told that Taiwan could be defended to
It should have been Maestro’s night. It is hard to envision a film more Oscar-friendly than Bradley Cooper’s exploration of the life and loves of famed conductor and composer Leonard Bernstein. It was a prestige biopic, a longtime route to acting trophies and more (see Darkest Hour, Lincoln, and Milk). The film was a music biopic, a subgenre with an even richer history of award-winning films such as Ray, Walk the Line and Bohemian Rhapsody. What is more, it was the passion project of cowriter, producer, director and actor Bradley Cooper. That is the kind of multitasking -for-his-art overachievement that Oscar
Chinese villages are being built in the disputed zone between Bhutan and China. Last month, Chinese settlers, holding photographs of Chinese President Xi Jinping (習近平), moved into their new homes on land that was not Xi’s to give. These residents are part of the Chinese government’s resettlement program, relocating Tibetan families into the territory China claims. China shares land borders with 15 countries and sea borders with eight, and is involved in many disputes. Land disputes include the ones with Bhutan (Doklam plateau), India (Arunachal Pradesh, Aksai Chin) and Nepal (near Dolakha and Solukhumbu districts). Maritime disputes in the South China